Nanotechnology in the treatment and detection of intraocular cancers

Journal of Biomedical Nanotechnology

Volumn 4, Issue 4, 2008, Pages 410-418

  Nair, Ashwin ^a   Thevenot, Paul ^a   Hu, Wenjing ^b   Tang, Liping ^a  

^a University of Texas at Arlington   (United States)

^b Progenitec Inc   (United States)

Author keywords

Drug delivery; Imaging; Intraocular cancer; Intravitreal injection; Liposomes; Nanoparticles; Quantum dots; Retinoblastoma; Uveal melanoma

Indexed keywords

DRUG DELIVERY; DRUG THERAPY; LIPOSOMES; NANOPARTICLES; NANOSTRUCTURED MATERIALS; NANOTECHNOLOGY; OPTICAL WAVEGUIDES; PHOSPHOLIPIDS; QUANTUM ELECTRONICS; SEMICONDUCTOR QUANTUM DOTS; TUMORS;

IMAGING; INTRAOCULAR CANCER; INTRAVITREAL INJECTION; QUANTUM DOTS; RETINOBLASTOMA; UVEAL MELANOMA;

MEDICAL NANOTECHNOLOGY;

ALPHA INTERFERON; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLODEXTRIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DENDRIMER; DOXORUBICIN; ETOPOSIDE; INTERLEUKIN 2; LIPOSOME; NANOCAPSULE; NANOPARTICLE; NANOSHELL; QUANTUM DOT; TAMOXIFEN; VINCRISTINE;

BINDING AFFINITY; BIOCOMPATIBILITY; BRACHYTHERAPY; DRUG TARGETING; ENUCLEATION; EXTERNAL BEAM RADIOTHERAPY; EYE CANCER; HUMAN; HYPERTHERMIC THERAPY; MATERIAL COATING; MOLECULAR IMAGING; MOLECULAR WEIGHT; NANODEVICE; NANOMEDICINE; NANOPHARMACEUTICS; NONHUMAN; OPTICAL COHERENCE TOMOGRAPHY; RETINOBLASTOMA; REVIEW; UVEA MELANOMA;

EID: 58149316189     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2008.004     Document Type: Review

References (85)

1. E. Hoppe and R. Frankel, Optometrists as key providers in the prevention and early detection of malignancies. Optometry 77, 397 (2006).
2. J. W. Harbour, Eye cancer: Unique insights into oncogenesis: The Cogan lecture. Invest. Ophthalmol. Vis. Sci. 47, 1736 (2006).
3. R. W. Weber, S. O'Day, M. Rose, R. Deck, P. Ames, J. Good, J. Meyer, R. Allen, S. Trautvetter, M. Timmerman, S. Cruickshank, M. Cook, R. Gonzalez, and L. E. Spitler, Low-dose outpatient chemobiotherapy with temozolomide, granulocyte-macrophage colony stimulating factor, interferon-alpha2b, and recombinant interleukin-2 for the treatment of metastatic melanoma. J. Clin. Oncol. 23, 8992 (2005).
4. P. L. Triozzi, C. Eng, and A. D. Singh, Targeted therapy for uveal melanoma. Cancer Treat. Rev. 34, 247 (2008).
5. S. R. Elshaw, K. Sisley, N. Cross, A. K. Murray, S. M. MacNeil, M. Wagner, C. E. Nichols, and I. G. Rennie, A comparison of ocular melanocyte and uveal melanoma cell invasion and the implication of alpha1beta1, alpha4beta1 and alpha6beta1 integrins. Br. J. Ophthalmol. 85, 732 (2001).
6. A. Damato, Developments in the management of uveal melanoma. Clin. Experiment Ophthalmol. 32, 639 (2004).
7. S. R. Boyd, D. Tan, C. Bunce, A. Gittos, M. H. Neale, J. L. Hungerford, S. Charnock-Jones, and I. A. Cree, Vascular endothelial growth factor is elevated in ocular fluids of eyes harbouring uveal melanoma: Identification of a potential therapeutic window. Br. J. Ophthalmol. 86, 448 (2002).
8. S. Pyrhönen, The treatment of metastatic uveal melanoma. Eur. J. Cancer 34, S27 (1998).
9. J. Atzpodien, E. Hanninen, and H. Kirchner, Chemoimmunotherapy of advanced malignant melanoma: Sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen. Eur. J. Cancer 31A, 876 (1995).
10. S. Peters, V. Voelter, L. Zografos, S. Pampallona, R. Popescu, M. Gillet, W. Bosshard, G. Fiorentini, M. Lotem, R. Weitzen, U. Keilholz, Y. Humblet, S. Piperno-Neumann, R. Stupp, and S. Leyvraz, Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: Experience in 101 patients. Ann. Oncol. 17, 578 (2006).
11. K. Mallikarjuna, P. Vaijayanthi, and S. Krishnakumar, Cripto-1 expression in uveal melanoma: An immunohistochemical study. Exp. Eye Res. 84, 1060 (2007).
12. M. H. Krause, K. K. Kwong, E. S. Gragoudas, and L. H. Young, MRI of blood volume with superparamagnetic iron in choroidal melanoma treated with thermotherapy. Magn. Reson. Imaging 22, 779 (2004).
13. A. B. Francken, M. J. Fulham, M. J. Millward, and J. F. Thompson, Detection of metastatic disease in patients with uveal melanoma using positron emission tomography. Eur. J. Surg. Oncol. 32, 780 (2006).
14. A. Leal-Leal, M. Flores-Rojo, A. Medina-Sanson, F. Cerecedo-Diaz, S. Sanchez-Felix, O. Gonzalez-Ramella, F. Perez-Perez, R. Gomez-Martinez, A. Quero-Hernandez, E. Altamirano-Alvarez, F. Alejo-Gonzalez, J. Figueroa-Carbajal, A. Ellis-Irigoyen, I. Tejocote-Romero, R. Cervantes-Paz, F. Pantoja-Guillen, L. Vega-Vega, and F. Carrete-Ramirez, A multicentre report from the Mexican retinoblastoma group. Br. J. Ophthalmol. 88, 1074 (2004).
15. Z. A. Karcioglu, S. A. Al-Mesfer, E. Abboud, M. H. Jabak, and P. B. Mullaney, Workup for metastatic retinoblastoma. A review of 261 patients. Ophthalmology 104, 307 (1997).
16. M. Chintagumpala, P. Chevez Barrios, E. A. Paysse, S. E. Plon, and R. Hurwitz, Retinoblastoma: Review of current management. Oncologist 12, 1237 (2007).
17. E. V. Smith, E. S. Gragoudas, N. H. Kolodny, and D. J. D'Amico, Magnetic resonance imaging: An emerging technique for the diagnosis of ocular disorders. Int. Ophthalmol. 14, 119 (1990).
18. D. Brenner, C. Elliston, E. Hall, and W. Berdon, Estimated risks of radiation-induced fatal cancer from pediatric CT. AJR Am. J. Roentgenol. 176, 289 (2001).
19. K. Coleman, J. P. Baak, P. Van Diest, J. Mullaney, M. Farrell, and M. Fenton, Prognostic factors following enucleation of 111 uveal melanomas. Br. J. Ophthalmol. 77, 688 (1993).
20. M. W. Wilson, G. Czechonska, P. T. Finger, A. Rausen, M. E. Hooper, and B. G. Haik, Chemotherapy for eye cancer. Survey of Ophthalmology 45, 416 (2001).
21. K. E. Schmid, G. V. Kornek, W. Scheithauer, and S. Binder, Update on ocular complications of systemic cancer chemotherapy. Survey of Ophthalmology 51, 19 (2006).
22. D. Sutton, N. Nasongkla, E. Blanco, and J. Gao, Functionalized micellar systems for cancer targeted drug delivery. Pharm. Res. 24, 1029 (2007).
23. C. G. Micames and F. G. Gress, Local EUS-guided injection of chemotherapeutic agents as adjuvant to systemic treatment: The first steps are made. Gastrointestinal Endoscopy 65, 454 (2007),
24. H. Kim, M. J. Lizak, G. Tansey, K. G. Csaky, M. R. Robinson, P. Yuan, N. S. Wang, and R. J. Lutz, Study of ocular transport of drugs released from an intravitreal implant using magnetic resonance imaging. Ann. Biomed. Eng. 33, 150 (2005).
25. J. L. Bourges, C. Bloquel, A. Thomas, F. Froussart, A. Bochot, F. Azan, R. Gurny, D. BenEzra, and F. Behar-Cohen, Intraocular implants for extended drug delivery: Therapeutic applications. Adv. Drug Del. Rev. 58, 1182 (2006).
26. B. A. Booth, L. V. Denham, S. Bouhanik, J. Jacob, and J. M. Hill, Sustained-release ophthalmic drug delivery systems for treatment of macular disorders: Present and future applications. Review article. Drugs & Aging 24, 581 (2007).
27. Y. Ali and K. Lehmussaari, Industrial perspective in ocular drug delivery. Adv. Drug Del. Rev. 58, 1258 (2006).
28. A. Urtti, Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv. Drug Deliv. Rev. 58, 1131 (2006).
29. Y. Sultana, R. Jain, M. Aqil, and A. Ali, Review of ocular drug delivery. Current Drug Delivery 3, 207 (2006).
30. E. Sakurai, H. Ozeki, N. Kunou, and Y. Ogura, Effect of particle size of polymeric nanospheres on intravitreal kinetics. Ophthalmic Res. 33, 31 (2001).
31. R. Cortesi, R. Argnani, E. Esposito, A. Dalpiaz, A. Scatturin, F. Bortolotti, M. Lufino, R. Guerrini, G. Cavicchioni, C. Incorvaia, E. Menegatti, and R. Manservigi, Cationic liposomes as potential carriers for ocular administration of peptides with anti-herpetic activity. Int. J. Pharm. 317, 90 (2006).
32. P. Chetoni, S. Rossi, S. Burgalassi, D. Monti, S. Mariotti, and M. F. Saettone, Comparison of liposome-encapsulated acyclovir with acyclovir ointment: Ocular pharmacokinetics in rabbits. J. Ocul. Pharmacol. Ther. 20, 169 (2004).
33. R. M. Mainardes, M. C. Urban, P. O. Cinto, N. M. Khalil, M. V. Chaud, R. C. Evangelista, and M. P. Gremiao, Colloidal carriers for ophthalmic drug delivery. Curr. Drug Targets 6, 363 (2005).
34. P. M. Hughes, O. Olejnik, J. E. Chang-Lin, and C. G. Wilson, Topical and systemic drug delivery to the posterior segments. Adv. Drug Deliv. Rev. 57, 2010 (2005).
35. K. G. Janoria, S. Gunda, S. H. S. Boddu, and A. K. Mitra, Novel approaches to retinal drug delivery. Expert Opin. Drug Deliv. 4, 371 (2007).
36. S. Raghava, M. Hammond, and U. B. Kompella, Periocular routes for retinal drug delivery. Expert Opin. Drug Deliv. 1, 99 (2004).
37. A. C. Amrite and U. B. Kompella, Size-dependent disposition of nanoparticles and microparticles following subconjunctival administration. J. Pharm. Pharmacol. 57, 1555 (2005).
38. A. C. Amrite, H. F. Edelhauser, S. R. Singh, and U. B. Kompella, Effect of circulation on the disposition and ocular tissue distribution of 20 nm nanoparticles after periocular administration. Mol. Vis. 14, 150 (2008).
39. J. Vandervoort and A. Ludwig, Ocular drug delivery: Nanomedicine applications. Nanomed. 2, 11 (2007).
40. M. I. Afouna, I. S. Khattab, and I. K. Reddy, Preparation and characterization of demeclocycline liposomal formulations and assessment of their intraocular pressure-lowering effects. Cutan. Ocul. Toxicol. 24, 111 (2005).
41. E. Vega, M. A. Egea, O. Valls, M. Espina, and M. L. Garcia, Flurbiprofen loaded biodegradable nanoparticles for ophthalmic administration. J. Pharm. Sci. 95, 2393 (2006).
42. J. L. Bourges, S. E. Gautier, F. Delie, R. A. Bejjani, J. C. Jeanny, R. Gurny, D. BenEzra, and F. F. Behar-Cohen, Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles. Invest. Ophthalmol. Vis. Sci. 44, 3562 (2003).
43. T. Yasukawa, Y. Tabata, H. Kimura, N. Kunou, and Y. Ogura, Development of drug-delivery systems to the posterior segments of the eye. Exp. Rev. Ophthalmol. 2, 197 (2007).
44. N. Bodor and P. Buchwald, Ophthalmic drug design based on the metabolic activity of the eye: Soft drugs and chemical delivery systems. The AAPS Journal 7, Article 79 (2005).
45. S. Barbault-Foucher, R. Gref, P. Russo, J. Guechot, and A. Bochot, Design of poly-ε-caprolactone nanospheres coated with bioadhesive hyaluronic acid for ocular delivery. J. Cont. Rel. 83, 365 (2002).
46. J. Hsu, Drug delivery methods for posterior segment disease. Retinal, vitreous and macular disorders. Curr. Opin. Ophthalmol. 18, 235 (2007).
47. S. Zhang, J. Zhou, Z. Hu, A. Nair, and L. Tang, Nanoparticles for uveal melanoma treatment. Proc. IEEE Nano2008 Conference (2008), pp. 822-825.
48. M. de Campos, Y. Diebold, E. L. Carvalho, A. Sanchez, and M. J. Alonso, Chitosan nanoparticles as new ocular drug delivery systems: In vitro stability, in vivo fate, and cellular toxicity. Pharm. Res. 21, 803 (2004).
49. J. A. Cardillo, L. A. S. Melo, Jr., R. A. Costa, M. Skaf, R. Belfort, Jr., A. A. Souza-Filho, M. E. Farah, and B. D. Kuppermann, Comparison of intravitreal versus posterior sub-tenon's capsule injection of triamcinolone acetonide for diffuse diabetic macular edema. Opthalmol. 112, 1557 (2005).
50. E. R. Thomas, J. Wang, E. Edge, R. Madsen, and D. P. Hainsworth, Intravitreal triamcinolone acetonide concentration after subtenon injection. Am. J. Ophthalmol. 142, 860 (2006).
51. H. Li, V. V. Tran, Y. Hu, W. M. Saltzman, C. J. Barnstable, and J. Tombran-Tink, A PEDF N-terminal peptide protects the retina from ischemic injury when delivered in PLGA nanospheres. Exp. Eye. Res. 83, 824 (2006).
52. A. Quintana, E. Raczka, L. Piehler, I. Lee, A. Myc, I. Majoros, A. K. Patri, T. Thomas, J. Mule, and J. R. Baker, Jr., Design and function of a dendrimer-based therapeutic nanodevice targeted to tumor cells through the folate receptor. Pharm. Res. 19, 1310 (2002).
53. E. Barbu, L. Verestiuc, T. G. Nevell, and J. Tsibouklis, Polymeric materials for ophthalmic drug delivery: Trends and perspectives. J. Mat. Chem. 16, 3439 (2006).
54. S. Kawakami, A. Harada, K. Sakanaka, K. Nishida, J. Nakamura, T. Sakaeda, N. Ichikawa, M. Nakashima, and H. Sasaki, In vivo gene transfection via intravitreal injection of cationic liposome/plasmid DNA complexes in rabbits. Int. J. Pharm. 278, 255 (2004).
55. X. Yuan, H. Li, and Y. Yuan, Preparation of cholesterol-modified chitosan self-aggregated nanoparticles for delivery of drugs to ocular surface. Carbohydr. Polym. 65, 337 (2006).
56. E. de Salamanca, Y. Diebold, M. Calonge, C. Garcia-Vazquez, S. Callejo, A. Vila, and M. J. Alonso, Chitosan nanoparticles as a potential drug delivery system for the ocular surface: Toxicity, uptake mechanism and in vivo tolerance. Invest. Ophthalmol. Vis. Sci. 47, 1416 (2006).
57. M. Merodio, J. M. Irache, F. Valamanesh, and M. Mirshahi, Ocular disposition and tolerance of ganciclovir-loaded albumin nanoparticles after intravitreal injection in rats. Biomaterials 23, 1587 (2002).
58. Z. Bu, H. J. Gukasyan, L. Goulet, X. J. Lou, C. Xiang, and T. Koudriakova, Ocular disposition, pharmacokinetics, efficacy and safety of nanoparticle-formulated ophthalmic drugs. Curr. Drug Metab. 8, 91 (2007).
59. L. P. De Jesus, H. R. Ihre, L. Gagne, J. M. Frechet, and F. C. Szoka, Jr., Polyester dendritic systems for drug delivery applications: In vitro and in vivo evaluation. Bioconjug. Chem. 13, 453 (2002).
60. R. Pignatello, C. Bucolo, G. Spedalieri, A. Maltese, and G. Puglisi, Flurbiprofen-loaded acrylate polymer nanosuspensions for ophthalmic application. Biomaterials 23, 3247 (2002).
61. Y. Kawashima, T. Niwa, T. Handa, H. Takeuchi, T. Iwamoto, and K. Itoh, Preparation of controlled-release microspheres of ibuprofen with acrylic polymers by a novel quasi-emulsion solvent diffusion method. J. Pharm. Sci. 78, 68 (1989).
62. M. De Campos, A. Sanchez, and M. J. Alonso, Chitosan nanoparticles: A new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A. Int. J. Pharm. 224, 159 (2001).
63. S. K. Sahoo, F. Dilnawaz, and S. Krishnakumar, Nanotechnology in ocular drug delivery. Drug Discov. Today 13, 144 (2008).
64. X. Gao, L. Yang, J. A. Petros, F. F. Marshall, J. W. Simons, and S. Nie, In vivo molecular and cellular imaging with quantum dots. Curr. Opin. Biotechnol. 16, 63 (2005).
65. B. Dubertret, P. Skourides, D. J. Norris, V. Noireaux, A. H. Brivanlou, and A. Libchaber, In vivo imaging of quantum dots encapsulated in phospholipid micelles. Science 298, 1759 (2002).
66. A. Nair, J. Shen, P. Thevenot, T. Cai, Z. Hu, and L. Tang, Novel quantum dots for enhanced tumor imaging. Proc. IEEE Nano2008 Conference (2008), pp. 650-653.
67. R. A. Schachar, W. Chen, B. K. Woo, B. K. Pierscionek, X. Zhang, and L. Ma, Diffusion of nanoparticles in to the capsule and cortex of a crystalline lens. Nanotechnology 19, 1 (2008).
68. A. Loo, A. Lowery, N. Halas, J. West, and R. Drezek, Immunotargeted nanoshells for integrated cancer imaging and therapy. Nano Lett. 5, 709 (2005).
69. D. J. Faber, M. E. J. van Velthoven, M. de Bruin, M. C. G. Aalders, F. D. Verbraak, C. Graf, and T. G. van Leeuwen, NAOMI: Nanoparticles assisted optical molecular imaging. Proc. SPIEE 6079, 607905 (2006).
70. O. Oyewumi, R. A. Yokel, M. Jay, T. Coakley, and R. J. Mumper, Comparison of cell uptake, biodistribution and tumor retention of folate-coated and PEG-coated gadolinium nanoparticles in tumor-bearing mice. J. Cont. Rel. 95, 613 (2004).
71. G. F. Paciotti, L. Myer, D. Weinreich, D. Goia, N. Pavel, R. E. McLaughlin, and L. Tamarkin, Colloidal gold: A novel nanoparticle vector for tumor directed drug delivery. Drug Deliv. 11, 169 (2004).
72. D. L. Holligan, G. T. Gillies, and J. P. Dailey, Magnetic guidance of ferrofluidic nanoparticles in an in vitro model of intraocular retinal repair. Nanotechnology 14, 661 (2003).
73. S. Ding, Recent developments in ophthalmic drug delivery. Pharm. Sc. Tech. Today 1, 328 (1998).
74. S.-F. Huang, J.-L. Chen, M.-K. Yeh, and C.-H. Chiang, Physicochemical properties and in vivo assessment of Timolol-loaded poly(D,L-lactide-co-glycolide) films for long-term intraocular pressure lowering effects. J. Ocul. Pharmacol. Ther. 21, 445 (2005),
75. C. Andrieu-Soler, A. Aubert-pouessel, M. Doat, S. Picaud, M. Halhal, M. Simonutti, M. C. Venier-Julienne, J. P. Benoit, and F. Behar-Cohen, Intravitreous injection of PLGA microspheres encapsulating GDNF promotes the survival of photoreceptors in the rd1/rd1 mouse. Molecular Vision 11, 1002 (2005).
76. T. J. De Faria, A. M. De Campos, and E. L. Senna, Preparation and characterization of poly(d,l-lactide) (PLA) and poly(d,l-lactide)-poly(ethylene glycol) (PLA-PEG) nanocapsules containing antitumoral agent methotrexate. Macromol. Symp. 229, 228 (2005).
77. T. Yasukawa, Y. Ogura, E. Sakurai, Y. Tabata, and H. Kimura, Intraocular sustained drug delivery using implantable polymeric devices. Adv. Drug Delivery Rev. 57, 2033 (2005).
78. N. R. F. Beeley, J. V. Rossi, P. A. Mello-Filho, M. I. Mahmoud, G. Y. Fujii, E. de Juan, Jr., and S. E. Varner, Fabrication, implantation, elution, and retrieval of a steroid-loaded polycaprolactone subretinal implant. J. Biomed. Mater. Res. 73A, 437 (2005).
79. M. Prabaharan and J. F. Mano, Chitosan-based particles as controlled drug delivery systems. Drug Delivery 12, 41 (2005).
80. Y.-H. Liao, Hyaluronan: Pharmaceutical characterization and drug delivery. Drug Delivery 12, 327 (2005).
81. Y. Cao, C. Zhang, W. Shen, Z. Cheng, L. Yu, and Q. Ping, Poly(N-isopropylacrylamide)-chitosan as thermosensitive in situ gelforming system for ocular drug delivery. J. Cont. Rel. 120, 186 (2007).
82. M. K. Yoo, K. Y. Cho, H. H. Song, and Y. J. Choi, Release of ciprofloxacin from chondroitin 6-sulfate-graft-poloxamer hydrogel in vitro for ophthalmic drug delivery. Drug Dev. Ind. Pharm. 31, 455 (2005).
83. K. Y. Cho, T. W. Chung, B. C. Kim, M. K. Kim, J. H. Lee, W. R. Wee, and C. S. Cho, Release of ciprofloxacin from poloxamers-graft-hyaluronic acid hydrogels in vitro. Int. J. Pharm. 260, 83 (2003).
84. S. Venkatesh, S. P. Sizemore, and M. E. Byrne, Biomimetic hydrogels for enhanced loading and extended release of ocular therapeutics. Biomaterials 28, 717 (2007).
85. W. Reiniger, A. Wolf, U. Welge-Lussen, A. J. Mueller, A. Kampik, and U. C. Schaller, Osteopontin as a serologic marker for metastatic uveal melanoma: Results of a pilot study. Am. J. Ophthalmol. 143, 705 (2007).